Logan Ridge Finance (NASDAQ:LRFC) Stock, Quote.Headers.trade-ideas

Logan Ridge Finance

Capitala Finance

Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.

Logan Ridge Finance Corporation - Common Stock

Logan Ridge Finance Corp

Goldman Sachs analyst David Roman maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Neutral and raises the price target from $58 to $80.

News

Price Target

Analyst Ratings

DOCS

Goldman Sachs Maintains Neutral on Doximity, Raises Price Target to $80

Contracts

CNVS

Cineverse Extends Its Partnership With Davis-Panzer Productions, Inc., Securing Digital Rights To Multiple Titles From The Iconic Highlander Film And Television Franchise

Blockchain-powered metaverse platform NetVRk on Monday introduced SilkAI, an artificial intelligence system designed to enhance virtual environments with <a href="https://www.benzinga.com/news/global/25/01/43149854/ai-ai-agents-will-create-unprecedented-opportunities-and-profound-risks-world-economic-forum-says">hyperintelligent AI agents and NPCs</a>.
The launch marks NetVRk's expansion into the AI sector, integrating lifelike digital companions into gaming and metaverse applications.
SilkAI&#8217;s system enables the creation of AI-driven 3D avatars and autonomous agents, designed to interact with users in real time, according to a release shared with Benzinga.
The AI technology focuses on realistic emotional mimicry, body language, and conversational depth, aiming to offer a more immersive virtual experience.
NetVRk's latest development follows an increasing demand for AI-powered digital interactions in metaverse platforms. 
SilkAI introduces self-learning AI agents that can function as independent influencers, generating content, engaging with audiences and managing digital accounts.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43596456/strategy-acquires-7633-bitcoin-for-742-4-million-boosts-holdings-to-478740-btc">Strategy Acquires 7,633 Bitcoin For $742.4 Million, Boosts Holdings To 478,740 BTC</a>
These agents are designed to integrate with gaming, live-streaming, and blockchain-based ecosystems through the forthcoming $SILKAI token.
According to NetVRk Co-founder and CEO Michael Katseli, &#8220;SilkAI is capitalizing on the rapid growth of the AI agent industry to enhance NetVRk&#8217;s ecosystem by integrating cutting-edge AI technology.&#8221; 
SilkAI also plans to introduce fully autonomous AI agents capable of functioning as influencers, managing accounts, creating content, and analyzing audiences.
SilkAI enters a market where AI-driven NPCs and metaverse interactions are seeing increased adoption. Competing with platforms like Character AI and Replika, SilkAI aims to attract users frustrated with restrictive filters and limited customization.
The company's approach could reshape how AI agents function in virtual economies, as NetVRk's broader metaverse strategy aligns with trends in AI-enhanced blockchain ecosystems. 
With SilkAI operating as a separate entity, NetVRk expects to maintain its development roadmap while leveraging AI's expanding role in virtual environments.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach &#8216;Billions&#8217; By 2030</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

NetVRk Launches SilkAI, Aims To Deliver Hyperintelligent AI Agents To Metaverse

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Raymond James analyst John Freeman downgraded ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) from Strong Buy to Outperform and lowered the price target from $157 to $124. ConocoPhillips shares closed at $98.36 on Friday. <a href="https://www.benzinga.com/quote/COP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Luke Sergott downgraded Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from Equal-Weight to Underweight and lowered the price target from $130 to $100. Illumina shares closed at $111.06 on Friday. <a href="https://www.benzinga.com/quote/ILMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst David Lebowitz downgraded Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Neutral and lowered the price target from $44 to $4. Pliant Therapeutics shares closed at $7.79 on Friday. <a href="https://www.benzinga.com/quote/PLRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Jon Windham downgraded the rating for Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Buy to Neutral and maintained the price target of $5. Altus Power shares closed at $4.87 on Friday. <a href="https://www.benzinga.com/quote/AMPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Susquehanna analyst Mehdi Hosseini downgraded NetApp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) from Positive to Neutral and lowered the price target from $155 to $130. NetApp shares closed at $122.91 on Friday. <a href="https://www.benzinga.com/quote/NTAP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ILMN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-1024x602.png" alt="" class="wp-image-774960" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10115830/image-82.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Downgrades

Markets

Trading Ideas

AMPS

ILMN

NTAP

PLRX

This Illumina Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Goldman Sachs analyst Andrea Tan maintains Day One Biopharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAWN#NASDAQ">DAWN</a>) with a Buy and lowers the price target from $48 to $43.

DAWN

Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $43

A recent <a href="https://www.reddit.com/r/wallstreetbets/comments/1ik2i8x/finally_received_the_coveted_what_the_fuck_are/">post</a> on r/wallstreetbets has triggered many reactions after an investor shared a letter from <a href="https://www.benzinga.com/money/fidelity-investments-review">Fidelity Investments</a>, warning them about their trading activity. The individual reportedly executed 3,385 trades in a single month, resulting in a $308,000 loss and as some said, should be &#8220;inducted into the WallStreetbets HOF with this letter.&#8221;&nbsp;
The investor, in response, jokingly reassured Fidelity by stating, &#8220;Fidelity, if you&#8217;re reading this, I can assure you that I am sufficiently leveraged within my personal risk tolerance. Stop killin&#8217; my vibe.&#8221;
Don't Miss:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>
Fidelity sent a letter telling the investor to check if their trading choices matched their &#8220;investment objectives, financial circumstances, and risk tolerance.&#8221; It was also made plain by the firm that Fidelity would assume that the investor was satisfied with the trading decisions and their results if they did not reply.
<h2 class="wp-block-heading">Reddit Reacts</h2>
The WallStreetBets community, which is known for <a href="https://www.benzinga.com/general/social-media/24/06/39299107/wallstreetbets-is-back-reddit-users-celebrate-massive-wins-on-apple-nvidia-bets-and-more">taking big risks with trading</a>, had mixed reactions. Some thought the letter was something to be proud of and even joked that the investor should frame it. Others noted that using borrowed funds and engaging in excessive trading could be extremely dangerous, as frequent, high-volume trading can result in substantial losses, particularly when using leveraged strategies.
Trending: They call it the &#8216;Biggest Disruption To IP Since Disney&#8217; and their funding window is closing . <a href="https://www.benzinga.com/money/elf-labs-1">Less than 2 days for investors to claim shares at just $2/share with $980 minimum.</a>
As one person said, &#8220;Imagine making 170 trades a day and still not making any money.&#8221; That&#8217;s in line with other, more satirical comments made by others. As one reader amusingly wrote, &#8220;Thank you for choosing Fidelity to help with your financial need of losing $308k in a month.&#8221; Another joked that this was the closest thing to a wellness check a brokerage would ever send.&nbsp;
Some saw it as a financial reality check, remarking that Fidelity was only upset because they couldn't charge commissions on losses. Others humorously referenced trading skills, stating that the investor "never had the makings of a varsity trader."
<h2 class="wp-block-heading">The Risks of Overtrading</h2>
Making thousands of trades in a short time is a risky way to invest and usually doesn't work well for most people. Fast <a href="https://www.benzinga.com/money/how-to-become-a-day-trader">trading like this</a> needs a lot of experience, good planning, and special tools. For everyday investors, it can mean paying a lot in fees and dealing with increased exposure to market volatility.
See Also: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
While some in the online trading community view this as an amusing event, it serves as a broader reminder of the importance of <a href="https://www.benzinga.com/money/fomo-trading">responsible investing</a>. Risk management, a <a href="https://www.benzinga.com/money/what-you-need-to-know-about-technical-analysis">well-thought-out strategy</a>, and an understanding of market conditions are crucial to long-term financial success.
As <a href="https://www.benzinga.com/money/best-stock-brokers-in-the-us">brokerage firms</a> like Fidelity step in with cautionary messages, it underscores the need for investors to periodically reassess their strategies to ensure they align with their financial objectives.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

'Stop Killin' My Vibe'—WallStreetBets Investor Gets A Letter From Fidelity After 3,385 Trades And A $300,000 Loss In 1 Month

BofA Securities analyst Justin Post maintained a Buy rating on Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google with a <a target="_blank" href="https://www.benzinga.com/quote/GOOGL/analyst-ratings" rel="noreferrer noopener">price target of $225</a>.
Statcounter January data indicates that Google&#8217;s global search share was up 5bps month-on-month (down 169bps year-on-year) to 89.8%, while Bing&#8217;s share was down 4bps M/M (up 51bps Y/Y) to 3.9%. Others (which include Yandex, Baidu Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bidu#NASDAQ">BIDU</a>), and Naver, but not ChatGPT) were up 1bps M/M (up 101bps Y/Y) to 5.0%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43596316/mondaycom-q4-earnings-beats-estimates-with-32-revenue-growth-ceo-highlights-ai-as-a-game-changer-for-2025" rel="noreferrer noopener">Monday.com Beats Q4 Earnings Estimates, Boasts 32% Revenue Growth: CEO Calls AI A Game-Changer</a>
The top share gainer in the Other category was Yandex (up 96bps Y/Y).
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10111815/newplot-3.png" alt="" class="wp-image-774875" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10111815/newplot-3.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10111815/newplot-3-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
In the US, Google&#8217;s share declined 5bps M/M (down 12bps Y/Y), with mobile down 5bps M/M (down 64bps Y/Y) and desktop up 53bps M/M (down 95bps Y/Y), while Bing&#8217;s share was up 7bps M/M (down 49bps Y/Y). Yahoo has gained 50bps Y/Y US share.
Given new AI entrants such as ChatGPT and Perplexity (which are not included in search share data), daily web visits (including desktop and mobile web) could be a better measure of AI competition than Search.
In January, global average daily web visits to Google were down 1% Y/Y (up 1% M/M) to 2.7 billion, ChatGPT was up 148% Y/Y (up 4% M/M) to 128 million, Bing was up 18% Y/Y (up 1% M/M) to 59 million.
In the US, Google visits were flat Y/Y (up 2% M/M) at 542 million, ChatGPT was up 96% Y/Y (up 4% M/M) to 18mn, Bing was down 9% Y/Y (down 3% M/M) to 12 million.
Data shows healthy growth among new AI platforms that Post tracks, but the combined daily web traffic is less than 0.3% of Google visits.
In January, Perplexity&#8217;s global traffic was up 279% year over year (up 6% M/M) to 3.2 million, and Claude&#8217;s was up 439% year over year (up 4% M/M) to 2.5 million.
Overall, Post did not observe a boost to Google&#8217;s traffic from AI Overviews but did not see a significant headwind from emerging AI search competition.
So far, ChatGPT and other AI-based engines do not appear to be materially impacting Google search traffic or share but could be capturing a healthy share of incremental AI-driven activity.
Post noted that traffic data are just estimates. On a fourth-quarter 2024 call, Google management emphasized healthy growth in Search volumes, aided by AI Overviews and Circle to search.
Given that the fourth quarter was another quarter of strong Search revenue growth, Post remained constructive on AI monetization benefits for Google Search. Also, the analyst&#8217;s recent channel checks suggest ads in the top position in AIOs are delivering higher CTRs and aiding search pricing.
Post projected fiscal 2025 sales of $328.59 billion and fiscal 2026 sales of $367.42 billion.
Price Action: GOOGL stock is up 0.94% at $187.08 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43593383/tower-semiconductor-q4-earnings-beats-eps-estimates-expands-ai-chip-production-for-2025-growth" target="_blank" rel="noreferrer noopener">Tower Semiconductor Q4 Earnings: Beats EPS Estimates, Expands AI Chip Production For 2025 Growth, Stock Falls As Outlook Disappoints The Street</a></li>
</ul>
Photo via Shutterstock

Reiteration

Tech

BIDU

GOOG

GOOGL

Google Faces Rising AI Rivals Like Baidu and Yandex But Analyst Sees Search and Ad Growth Holding Strong

General Dynamics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GD#NYSE">GD</a>) short percent of float has fallen 29.34% since its last report. The company recently reported that it has 2.90 million shares sold short, which is 1.18% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>General Dynamics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739206826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for General Dynamics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing General Dynamics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, General Dynamics's peer group average for short interest as a percentage of float is 3.67%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into General Dynamics's Recent Short Interest

SES AI's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) short percent of float has fallen 38.0% since its last report. The company recently reported that it has 11.16 million shares sold short, which is 6.46% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SES AI Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739206821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SES AI has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SES AI's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SES AI's peer group average for short interest as a percentage of float is 13.26%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into SES AI's Recent Short Interest

Modine Manufacturing's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) short percent of float has risen 8.33% since its last report. The company recently reported that it has 3.47 million shares sold short, which is 7.54% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Modine Manufacturing Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739206816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Modine Manufacturing has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Modine Manufacturing's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Modine Manufacturing's peer group average for short interest as a percentage of float is 7.18%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Modine Manufacturing's Recent Short Interest

Goldman Sachs analyst Will Nance maintains Affirm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) with a Buy and raises the price target from $78 to $90.

AFRM

Goldman Sachs Maintains Buy on Affirm Holdings, Raises Price Target to $90

Macro Economic Events

WIIM

Economics

SPDR Dow Jones Industrial Average ETF Trust

Major indexes are higher amid strength in tech stocks. Additionally, US metals stocks rose on reports of The US imposing steel and aluminum tariffs.

On Monday, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated steatohepatitis (MASH), respectively.
AdvanCell <a target="_blank" href="https://www.businesswire.com/news/home/20250210990350/en/AdvanCell-Enters-Into-Strategic-Collaboration-with-Lilly-to-Advance-Novel-Targeted-Alpha-Therapies-for-the-Treatment-of-Cancer" rel="noreferrer noopener">announced</a> that it is expanding the scope and breadth of its strategic collaboration with Eli Lilly to research and develop cancer treatments.
Under this new agreement, the parties will leverage AdvanCell's proprietary Pb-212 production technology, radionuclide development infrastructure, and Lilly's drug candidate programs to facilitate the development and accelerate the clinical advancement of an expanded portfolio of targeted alpha therapies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43558004/eli-lillys-recently-approved-inflammatory-bowel-disease-drug-shows-sustained-and-durable-treatment-at-two-years" rel="noreferrer noopener">Eli Lilly's Recently Approved Inflammatory Bowel Disease Drug Shows Sustained And Durable Treatment At Two Years</a>
In 2023, Eli Lilly acquired&nbsp;POINT Biopharma Global&nbsp;at $12.50 per share in cash, an aggregate of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35060421/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today" rel="noreferrer noopener">approximately $1.4 billion</a>.
In June 2023, POINT Biopharma and AdvanCell <a target="_blank" href="https://www.globenewswire.com/news-release/2023/06/26/2694358/0/en/POINT-Biopharma-and-AdvanCell-to-Collaborate-in-the-Development-of-Lead-212-Labeled-Radioligands.html" rel="noreferrer noopener">collaborated</a> on developing a global&nbsp;212Pb radioisotope and radioligand supply chain and drug manufacturing network for&nbsp;212Pb-labeled radioligands by each company.
Financial terms of the agreement were not disclosed.
Concurrently, Korea-based OliX Pharmaceuticals Inc. announced a global licensing agreement with Eli Lilly for the development and commercialization of OliX's OLX75016, a Phase 1 candidate primarily targeting metabolic-associated steatohepatitis (MASH) and other cardiometabolic indications.
OliX will <a target="_blank" href="https://www.businesswire.com/news/home/20250210958713/en/OliX-and-Lilly-Enter-Global-Licensing-Agreement-for-MASH-and-Other-Cardiometabolic-Indications" rel="noreferrer noopener">receive</a> an initial payment from Lilly to complete the Phase 1 clinical trial underway in Australia.
In preclinical studies, OliX has demonstrated the efficacy of OLX75016 in addressing MASH, liver fibrosis, and other cardiometabolic indications.
Recently, Eli Lilly reported fourth-quarter revenue of $13.53 billion, up 45% year over year, almost in line with the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43525518/eli-lilly-q4-earnings-strong-demand-for-mounjaro-but-prices-dip-forecasts-over-30-jump-in-2025-sales-on-newer-medicines" rel="noreferrer noopener">consensus of $13.57 billion</a>.
The increase was driven by a 48% increase in volume, partially offset by a 4% decrease due to lower realized prices.
Price Action: LLY stock is down 1.40% at $865.99 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43597552/whats-going-on-with-cisco-systems-stock-today" target="_blank" rel="noreferrer noopener">Cisco Unveils First Jointly Developed AI Agent From Mistral AI Partnership &#8211; What's On The Cards?</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

General

Eli Lilly Seeks To Expand Into Cancer Radiopharma And Fatty Liver, With Two Global Deals

HC Wainwright &amp; Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMX#NASDAQ">IMMX</a>) with a Buy and maintains $7 price target.

IMMX

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

Legal

MSFT

Microsoft Confirms Being Targeted By French Antitrust Probe, Adding Company "Fully Cooperating" With The Investigation

HC Wainwright &amp; Co. analyst Yi Chen reiterates OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) with a Buy and maintains $7 price target.

OKYO

HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>B of A Securities analyst John Murphy upgraded the rating for Mobileye Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) from Underperform to Neutral and raised the price target from $12 to $19. Mobileye Global shares closed at $16.07 on Friday. <a href="https://www.benzinga.com/quote/MBLY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets analyst Tim Savageaux upgraded MACOM Technology Solutions Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) from Market Perform to Outperform and raised the price target from $105 to $140. MACOM Technology shares closed at $127.21 on Friday. <a href="https://www.benzinga.com/quote/MTSI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Luke Sergott upgraded Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) from Underweight to Equal-Weight and raised the price target from $135 to $145. Agilent shares closed at $145.21 on Friday. <a href="https://www.benzinga.com/quote/A/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Amit Mehrotra upgraded Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) from Neutral to Buy and raised the price target from $90 to $103. Johnson Controls shares closed at $87.65 on Friday. <a href="https://www.benzinga.com/quote/JCI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods analyst Catherine Mealor upgraded Wesbanco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSBC#NASDAQ">WSBC</a>) from Market Perform to Outperform and raised the price target from $40 to $44. Wesbanco shares closed at $35.42 on Friday. <a href="https://www.benzinga.com/quote/WSBC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Agilent stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10114856/image-81-1024x572.png" alt="" class="wp-image-774932" style="width:678px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10114856/image-81-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10114856/image-81-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10114856/image-81-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/10114856/image-81.png 1095w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/02/43593480/wall-streets-most-accurate-analysts-give-their-take-on-3-real-estate-stocks-with-over-6-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Real Estate Stocks With Over 6% Dividend Yields</a></li>
</ul>

Upgrades

MBLY

MTSI

WSBC

This Agilent Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Needham analyst Ami Fadia reiterates Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) with a Buy and maintains $133 price target.

AXSM

Needham Reiterates Buy on Axsome Therapeutics, Maintains $133 Price Target

Innovator Capital Management rolled out the Uncapped Bitcoin 20 Floor ETF – Quarterly (BATS:<a class="ticker" href="https://www.benzinga.com/stock/QBF#BATS">QBF</a>), on Feb. 6, with a competitive <a href="https://www.benzinga.com/topic/bitcoin-etf">expense ratio of 0.79%.</a>
The <a href="https://www.benzinga.com/etfs">ETF offers investors exposure</a> to Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price movements while safeguarding investments against significant losses, allowing investors to capture up to 80% of Bitcoin's positive price swings over a quarterly period.
The launch of QBF comes at a time when demand for cryptocurrency exposure is surging, as the crypto world becomes more regulated. However, many investors remain cautious about invest in the volatile asset class. One important differentiating factor of this ETF is it ensures that investors will not lose more than 20% of any price decline, putting hesitant investors at ease.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43596456/strategy-acquires-7633-bitcoin-for-742-4-million-boosts-holdings-to-478740-btc">Strategy Acquires 7,633 Bitcoin For $742.4 Million, Boosts Holdings To 478,740 BTC</a>
Unlike traditional Bitcoin ETFs that invest directly in the cryptocurrency, QBF tracks Bitcoin's price movements in a controlled manner. This approach offers investors and financial advisors a structured way to gain crypto exposure without the full brunt of market turbulence.
&#8220;The Fund provides investment exposure to the price return of bitcoin (i.e., "spot" bitcoin prices) (the&nbsp;"Bitcoin Price") by investing in a combination of FLexible EXchange&nbsp;Options ("FLEX Options") that reference one or more exchange-traded&nbsp;products that hold bitcoin directly (each, a&nbsp;"Bitcoin ETP") or the CBOE Bitcoin U.S. ETF Index,&#8221; read an excerpt from its prospectus submitted with the SEC.
&#8220;The Fund seeks to provide shareholders that hold Shares for the entire Outcome Period with a maximum loss experienced by the Bitcoin Price of 20% (the&nbsp;"Floor") over the course of the Outcome Period by holding 80% of the Fund's assets in U.S. Treasuries in order to preserve the Fund's capital in the event the FLEX Options expire worthless,&#8221; the prospectus further read.
The cryptocurrency ETF market continues to expand, with investors increasingly seeking innovative investment solutions. 
As Bitcoin and the broader cryptocurrency market mature, funds like QBF signal a shift toward structured, risk-managed investment products that are suitable for seasoned investors as well as newcomers looking for safer exposure to digital assets.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43591727/coinbase-ceo-brian-armstrong-says-bitcoin-adoption-to-reach-billions-by-2030">Coinbase CEO Brian Armstrong Says Bitcoin Adoption To Reach &#8216;Billions&#8217; By 2030</a></li>
</ul>
Photo: Shutterstock

New ETFs

ETFs

$BTC

Innovator ETFs Trust Innovator Uncapped Bitcoin 20 Floor ETF - Quarterly

New Bitcoin ETF Limits Losses To 20%, Offers Risk-Controlled Exposure

RBC Capital analyst Drew McReynolds maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Sector Perform and lowers the price target from C$40 to C$39.

TSX:BCE

RBC Capital Maintains Sector Perform on BCE, Lowers Price Target to C$39

Press Releases

Logan Ridge Finance Corporation Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call

Portman Ridge Finance Corporation and Logan Ridge Finance Corporation Enter into Merger Agreement

Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Logan Ridge Finance Corporation Is Obtaining a Fair Price for Its Public Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Logan Ridge Finance Corporation - LRFC

LRFC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Logan Ridge Finance Corporation Is Fair to Shareholders

Kuehn Law Encourages PTMN, LRFC, ATSG, and ROIC Investors to Contact Law Firm

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TGI, PTMN, LRFC, SGBX on Behalf of Shareholders

LOGAN RIDGE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Logan Ridge Finance Corporation - LRFC

Comments

Logan Ridge Finance

Logan Ridge Finance (NASDAQ:LRFC) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga